Scientist I, Gene Therapy Vector Engineering / 遺伝子治療ベクター開発研究員
Role summary
Written by MyIslandJob from the job title and employer. See the employer's page for the full description.
Scientist I, Gene Therapy Vector Engineering is an early-career research role based in Japan, focused on designing, developing and improving gene therapy vectors, likely including viral platforms such as AAV. Candidates are generally expected to hold a relevant master's degree or PhD in molecular biology, biotechnology, virology, cell biology, pharmaceutical sciences or a related discipline. Practical experience with vector construction, cell culture, transfection, molecular biology assays, protein or genome analysis, and laboratory data interpretation is valuable. The role requires careful experimental planning, accurate documentation, scientific problem-solving and effective collaboration across research teams. Candidates should demonstrate curiosity, adaptability, strong communication skills and the ability to work in an international environment. Japanese and English proficiency may be useful, depending on team requirements.
Can I work in Japan?
Never pay anyone for a visa or a job offer. A real employer pays the permit costs and never asks you for money.
How it works
How it works: Nurses and allied health need a Japanese licence (the exam is in Japanese) for the Medical Services visa; pharma and medtech office jobs use the degree visa instead.
Before you apply: Nurses, doctors and most allied health staff must be registered or licensed locally before they start: expect checks on your degree and licence, often an English test, and often an exam or an assessment. Ask the employer who handles it and how long it takes. Most pharma and device office jobs do not need it.
Watch for: Indonesians and Filipinos can come as EPA nurse candidates and work while studying for the national exam; there is a time limit to pass.
Official source: Immigration Services Agency: Medical Services status of residence. Checked November 2026.
What the job usually comes with in Japan
Usual for Healthcare jobs in Japan, varies by employer. Checked November 2026.
| Registration | Japanese national licence needed; the exam is in Japanese |
|---|---|
| Relocation | Varies; expat transfers often include moving costs; the Certificate of Eligibility has no fee |
| Housing | Varies; some big firms offer company housing or an allowance, and expat packages include housing |
| Flights | Varies |
| Contract | Usually open-ended for full-time staff; dismissal needs an objectively reasonable cause (by law) |
| Leave | 10 days' paid leave after 6 months, up to 20 after 6.5 years (by law); 16 national holidays |
| Income tax | 5% to 45% national (20% from JPY 3.3m taxable) plus 10% local tax from year 2; about 15% social insurance |
Senior staff often get more than line staff, for example a single room or a yearly home flight. Ask the employer what the job includes before you accept.
Guidance, not legal advice. Rules change; your employer confirms the details for your case.
About Astellas Pharmaceutical
Astellas Pharma Inc. is a Japan-based global pharmaceutical company headquartered in Tokyo, with research, development and commercial operations across major international markets. The company focuses on innovative medicines in areas such as oncology, immunology, ophthalmology, urology, neuroscience and rare diseases. Astellas also invests in emerging technologies, including cell therapy, gene therapy and advanced biologics, with the aim of addressing diseases where treatment options remain limited. Its research organization combines discovery science, translational medicine, clinical development and manufacturing capabilities. Employees typically work in multidisciplinary and internationally connected teams, collaborating with academic institutions, biotechnology companies and healthcare professionals. Astellas promotes scientific innovation, patient-centered development, compliance and diversity. The advertised gene therapy vector engineering position would likely support the company’s efforts to create robust, scalable and clinically useful genetic medicines.